|
Thursday, 03 May 2012 11:19 |
|
CALGARY, AB--Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) announced today that it has entered into an agreement whereby the NCIC Clinical Trials Group (CTG) at Queen's University in Kingston, Ontario, will sponsor and conduct a randomized Phase II study of REOLYSIN® in patients with advanced or metastatic colorectal cancer.
|
|
Read more...
|
|
Friday, 16 March 2012 19:11 |
 Below is a look at some of the headlines for companies that made news in the healthcare sector on March 16, 2012.
|
|
Read more...
|
|
Tuesday, 06 March 2012 19:04 |
|
QUEBEC CITY--Medicago Inc. (TSX: MDG.TO), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced the establishment of a strategic alliance with Mitsubishi Tanabe Pharma Corporation (MTPC) through the execution of a Master Research Collaboration Agreement.
|
|
Read more...
|
|
Tuesday, 31 January 2012 18:52 |
|
YOKNEAM, ISRAEL--Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company, today announced that it will release fourth quarter 2011 financial results before the market opens on Thursday, February 9, 2012.
|
|
Read more...
|
|
Tuesday, 31 January 2012 18:50 |
|
SHANGRI-LA COUNTY, CHINA--Tibet Pharmaceuticals, Inc. (NASDAQ: TBET), an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, today announced that it has signed a Letter of Intent ("LOI") to cooperate with Anhui Taihe Pharmaceutical Group Co., Ltd. ("Anhui Taihe Pharmaceutical Group"), a wholesale pharmaceutical distribution company based in Anhui province with a network across 16 provinces and municipalities in China.
|
|
Read more...
|
|
Tuesday, 15 November 2011 21:57 |
|
CALGARY, AB --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) (“Oncolytics”) today announced that interim results from a Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with gemcitabine (Gemzar®) in patients with advanced pancreatic cancer will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
|
|
Read more...
|
|
Monday, 14 November 2011 21:06 |
|
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB.PK) (Pinksheets: KBLB.PK) (the “Company” or "Kraig") announced that researchers at the University of Notre Dame, utilizing customized zinc finger configurations licensed to Kraig from Sigma-Aldrich, succeeded in creating seven or more strains of transgenically modified silkworms.
|
|
Read more...
|
|
Monday, 14 November 2011 20:51 |
|
FISHERS, Ind.--Positron Corporation (OTCBB:POSC.OB - News), a leading molecular imaging company specializing in the field of nuclear cardiology is pleased to announce today that on Friday November 11, 2011, Positron and Manhattan Isotope Technology LLC. (MIT LLC) entered into a binding Letter of Intent to acquire MIT LLC. The transaction will close January 2, 2012 upon execution of final transaction documents.
|
|
Read more...
|
|
Thursday, 03 November 2011 19:00 |
|
DÜSSELDORF, GERMANY - ImmunAid Pty. Ltd. has been awarded a European patent for its pioneering work in the treatment of cancer, based on monitoring the immune cycle of each individual patient and then determining the optimal time to deliver treatment to that patient.
|
|
Read more...
|
|
Monday, 02 May 2011 10:37 |
|
ANNAPOLIS, Md. -- PharmAthene, Inc. (NYSE Amex: PIP) announced today that closing arguments in its breach of contract action against SIGA Technologies were held on Friday, April 29, 2011 in the Delaware Court of Chancery. Post trial briefs in the case were submitted by both parties to the Court in April 2011.
|
|
Read more...
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
|
|
Page 1 of 65 |
